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Abstract
Objectives Relatively little is known about the incidence of long-
term renal damage after renal denervation (RDN), a potential new
treatmentforhypertension. Inthisstudytheincidenceofrenalartery
and parenchymal changes, assessed with contrast-enhanced mag-
netic resonance angiography (MRA) after RDN, is investigated.
Methods This study is an initiative of ENCOReD, a collabo-
ration of hypertension expert centres. Patients in whom an
MRA was performed before and after RDN were included.
Scans were evaluated by two independent, blinded radiolo-
gists. Primary outcome was the change in renal artery mor-
phology and parenchyma.
Results MRAs from 96 patients were analysed. Before RDN,
41 renal anomalies were observed, of which 29 mostly mild
renal artery stenoses. After a median time of 366 days post
RDN, MRA showed a new stenosis (25–49% lumen reduc-
tion) in two patients and progression of pre-existing lumen
reduction in a single patient. No other renal changes were
observed and renal function remained stable.
Conclusions We observed new or progressed renal artery ste-
nosis in three out of 96 patients, after a median time of
12 months post RDN (3.1%). Procedural angiographies
showed that ablations were applied near the observed stenosis
in only one of the three patients.
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• The incidence of vascular changes 12 months post RDN was
3.1%.
• No renal vascular or parenchymal changes other than ste-
noses were observed.
• Ablations were applied near the stenosis in only one of three
patients.
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CKD-EPI Chronic Kidney Disease Epidemiology
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ENCOReD European Network COordinating research on
Renal Denervation
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Introduction
Despite promising initial results, the efficacy of renal artery
denervation (RDN) for lowering blood pressure (BP) is still
subject of discussion [1, 2]. RDN, a relatively new treatment
modality for hypertension, is achieved through an
endovascular procedure by catheter-based radiofrequency ab-
lation of the renal arteries [1, 3]. Because of the nature of this
intervention, there is obvious concern about possible damage
to the renal artery and parenchyma. This concern was fuelled
by the findings of Templin et al., who analysed the incidence
of renal vascular changes before and directly after RDN by
optical coherence tomography [4]. In 24 renal arteries the
authors observed a high occurrence of vascular changes;
42% of renal arteries showed vasospasm, 13% showed a
dissection and there was a significant increase in the occur-
rence of oedema and thrombi [4]. The clinical significance of
these findings is not completely understood. Several case
reports demonstrated angiographically documented renal
artery stenosis after RDN [5–9]. Also, clinical studies reported
on vascular changes as assessed with renal artery imaging
before and after RDN [10–18]. Since there is considerable
variation across these studies with respect to imaging
modality, follow-up time and definitions used for abnormali-
ties, there is a clear need for more detailed information on
long-term safety.
The present study aimed to investigate the safety of RDN
by assessing systematically the incidence of morphological
changes in renal arteries and parenchyma after RDN,
compared to baseline, using magnetic resonance angiography
of the renal arteries and kidneys.
Material and methods
Study population
The present study is an initiative of the European Network
COordinating research on Renal Denervation (ENCOReD),
an international collaboration of hypertension expert centres
performing RDN (Table 5 of the Supplementary Material)
[19].We composed a cohort of patients who met the following
criteria: age ≥18 years, treated with catheter-based radiofre-
quency RDN and available MRA imaging 0–12 months be-
fore RDN andMRA imaging after RDN, regardless of follow-
up time. There were no further criteria with regard to indica-
tion for treatment, BP level or type of RDN catheter.
Data were collected from routine medical care or previous-
ly performed RDN studies that were approved by local med-
ical ethics committees, in accordance with the Declaration of
Helsinki and Title 45, US Code of Federal Regulations, Part
46, Protection of Human Subjects (Table 6 of the
Supplementary Material) [20–25]. The methods of measure-
ments are described in the original studies.
RDN procedure
Assessment of indication and eligibility for RDN was per-
formed by the treating physician or according to the centre-
specific study protocol. Procedural aspects, such as location
and number of ablations and which arteries to treat, were left
to the operator’s discretion. RDN was performed by catheter-
based radiofrequency ablation [1, 3]. Digital subtraction angi-
ography (DSA) or normal angiography of the renal arteries
was performed just before and after the procedure.
Magnetic resonance angiography
In order to determine anatomical eligibility for RDN, contrast-
enhanced MRA of the kidneys was performed at baseline.
According to the centre-specific standard of care a routine
follow-up MRA was performed after RDN. This MRA was
offered to all consecutive patients and none of the examina-
tions was performed based on a specific clinical indication.
Details of imaging protocols and technical settings of the
MRA were centre-specific and can be found in Table 7 of
the Supplementary Material.
Imaging assessment
All individual scans were anonymised and collected from the
centres. Images were re-evaluated independently by two
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radiologists (PJD, JH) at the University Medical Centre
Utrecht (UMCU), the core-lab for this study. Images were
blinded for date and centre and assessed for abnormalities in
the kidney or renal artery in a standardized fashion using a
scoring form (provided in Table 8 of the Supplementary
Material). Pre- and post-scans were evaluated in a random
order and not as pairs. Abnormalities were visually identified
and outcomes were scored per renal artery and per kidney.
Whenever there were discrepancies between the observers, a
third radiologist (TL) was consulted to reach consensus. All
observed abnormalities were also evaluated by the third radi-
ologist, unblinded for scan date. To assess whether anomalies
could be attributed to the ablation, follow-up MRA examina-
tions (for those showing abnormalities) were compared to
intra-arterial DSA images, obtained during RDN.
Outcome parameters
Primary outcome was the difference in renal artery and paren-
chyma morphology between baseline and follow-up.
Abnormalities were defined as follows:
– Renal artery stenosis: focal luminal narrowing (category
1: stenosis of <25%, category 2: stenosis 25–49%, cate-
gory 3: stenosis 50–74%, category 4: stenosis ≥75%, cat-
egory 5: occlusion of the renal artery).
– Renal artery aneurysm: defined as a local increase in ar-
tery diameter of at least 20% compared to the closest
adjacent normal segment.
– Renal artery dissection: presence of an intimal flap in the
renal artery (flow limiting or non-flow limiting).
– Kidney infarction: sharply marginated area of hypoperfu-
sion or cortical retraction.
Renal incidentalomas,nototherwisespecified,werealsoscored.
Additional assessments
We collected patient-related characteristics, both at baseline
and at follow-up, and procedural details of the total popula-
tion. Most of the patients were also reported in previously
published studies [19, 20]. Kidney function was assessed by
serum creatinine and by calculation of estimated glomerular
filtration rate (Chronic Kidney Disease Epidemiology
Collaboration (CKD-EPI) equation) [26].
In addition, kidney length was measured at baseline and
follow-up by MR images.
Data analysis
Data are presented as means with corresponding standard de-
viations (SDs), as medians with range or interquartile range
(IQR), or as percentages. Primary outcome is presented as
frequency of observed abnormalities and as incidence of
change. A 95% confidence interval (CI) for the incidence
was calculated. Paired-samples t-tests were used to assess dif-
ferences in patient characteristics and kidney length before
and after RDN.
Analyses were performed using the IBM SPSS Statistics
for Windows, Version 21.0 (IBM Corp., Armonk, NY, USA).
Results
Baseline characteristics
Originating from four European RDN centres, 194 MRAs
from 97 patients were considered eligible for scoring. One
patient was excluded due to poor image quality, leaving 96
subjects and 192 MRAs for final analysis.
Patients were treated with RDN between November 2009
and September 2013. In all patients the indication for RDN
was resistant hypertension, defined as an office systolic BP
(SBP) ≥140 mmHg, despite the use of at least three BP-
lowering drugs, among which was a diuretic [27]. Median
time between baseline MRA and RDN was 61 days (IQR
12–114) and between RDN and follow-up MRA 366 days
(IQR 213–397). In total, the median time between the two
MRAs was 434 days (IQR 358–502). Table 1 shows the pa-
tient and procedural characteristics. Ninety-two patients were
treated with the Symplicity™ RDN catheter (Medtronic Inc.,
Santa Rosa, CA, USA). Other devices used are EnligHTN™
multi-electrode RDN system (St Jude Medical, St Paul, MN,
USA) (twice), OneShot™ RDN System (Covidien,
Mansfield, MA, USA) and Vessix™ RDN System (Boston
Scientific, Marlborough, MA, USA). The mean number of
ablations per artery was 6 ± 1.4. No major peri-procedural
adverse events occurred. Mean office BP at baseline was
187/104 ± 30/16 mmHg and mean baseline eGFR was 81 ±
19 ml/min/1.73 m2.
Renal artery anatomy
In total, 192 kidneys and 229 renal arteries were evaluated.
Twenty-eight out of 96 patients had accessory renal arteries
(Table 1). Except for one patient, all patients were treated in
both main renal arteries. Sixteen percent of the accessory renal
arteries were treated with RDN. Based on the OKADA clas-
sification, a tool to assess anatomical eligibility for RDN, 15%
of the patients had one or two kidneys that would be consid-
ered ineligible for the procedure [28].
Renal artery and parenchymal findings
Table 2 shows thescoringresultsof theMRAspreandpostRDN
separately. All individual abnormalities were counted. Before
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RDN, 31 vascular abnormalities in 25 patients were observed,
which represents a prevalence of 26.0% (95% CI 17.1–35.0) of
the patients (25 out of 96) and 15.7% (95%CI 10.7–20.8) of the
treated renal arteries (31 out of 197). Twenty-three patients had a
renalarterystenosisatbaseline;13patientshadalumenreduction
of <25%, nine patients 25–49% and one patient >50% (in an
untreated accessory renal artery). Six patients showed a second
renal artery stenosis, of which two had a lumen reduction of 25–
49% and the remainder <25%. The remaining lumen diameter
wasconsideredsufficient forRDNbythetreatingphysician.Two
of the 25 patients with pre-existing renal vascular abnormalities
had an aneurysm.
After RDN, in two patients a new renal artery stenosis was
observed (lumen reduction in both cases 25–49%) and in one
patient there was progression of a pre-existing lumen reduc-
tion (from <25% to 50–74%). Two of the three patients with
vascular changes were treated with the Symplicity™ catheter
and one with the EnligHTN™ multi-electrode system.
In both patients with an aneurysm at baseline, the renal
artery diameter did not increase further during follow-up.
Throughout the cohort, no new aneurysms or renal artery dis-
sections were observed. In two patients, kidney tissue
infarction was observed at baseline and, with the same sever-
ity, after RDN.
In total, the incidence of vascular changes over the ob-
served time period after RDN was 3.1% (95% CI −0.4 to
6.7) of treated patients and 1.5% (95% CI −0.2 to 3.2) of
treated arteries.
Mean kidney length at baseline was 113 ± 12 mm on the
left side and 109 ± 12 mm on the right side (Table 9 of the
Supplementary Material). Kidney length did not significantly
change after RDN (p = 0.78 on the left and p = 0.68 on the
right).
To assess the possible relationship between vascular chang-
es and the radiofrequency ablations, we analysed the DSA
images performed during RDN. In only one of the three pa-
tients with vascular changes after RDN we could conclude
that ablations were applied near the location where on the
follow-up MRA a new stenosis was observed (Fig. 1).
Furthermore, we concluded that findings on the pre-
procedural MRA corresponded to the DSA images.
Follow-up parameters
Table 3 shows patient-related parameters during the follow-up
MRA. Mean office SBP and DBP were significantly lower
compared to baseline. There were no differences in prescribed
medication. Importantly, kidney function remained
unchanged.
Table 4 presents the individual characteristics of the pa-
tients with newly observed or progressed renal artery stenosis.
Only one of the three patients showed a marked decrease in
BP. No other clinical signs (i.e. impaired kidney function) of
Table 1 Baseline characteristics of the study population
All patients (n = 96)
Age (years) 57 (range 35–80)
Sex, % male/female 55/45
Caucasian, % 93
Body mass index (kg/m2) 29 ± 5
Co-morbidity, %
Diabetes mellitus type 2 24
Cardiovascular diseases 19
Cerebrovascular diseases 7
Prescribed antihypertensive drugs, no. 4 (IQR 3–6)
Office SBP/DBP (mmHg) 187/104 ± 30/16
Office heart rate (bpm) 73 ± 14
eGFR (ml/min/1.73 m2) 81 ± 19
Patients with accessory renal arteries, no. (%) 28 (29)
Categorization of renal artery anatomy
Eligible anatomy, % (A1 or A2) 85
Non-eligible, % (A3, B1 or B2) 15
Renal arteries treated, no. 197
Time baseline MRA –RDN in days 61 (IQR 12–114)
Symplicity device used, no. 92
Other device used, no. 4
Ablations per artery, no. 6.0 ± 1.4
Major procedural complications, % 0
Data are presented as mean ± SD, unless stated otherwise
SBP systolic blood pressure;DBP diastolic blood pressure; bpm beats per
minute; eGFR estimated glomerular filtration rate; MRA magnetic reso-
nance angiography; RDN renal denervation
Table 2 Renal vascular (only treated arteries) and parenchymal
observations, after assessment by the senior radiologist
Pre Post
Renal artery stenosis 29 31




Of which second stenosis 6 6
Renal artery aneurysm 2 2
Renal artery dissection 0 0
Kidney infarction 2 2
<20% 1 1
>20% 1 1
Kidney-related incidentalomas 8 8
Cortical tissue loss 5 5
Other focal lesion 2 2
Unilateral small kidney 1 1
Absolute numbers are presented
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renal artery stenosis were reported. Also in these patients,
kidney length did not change after RDN.
Discussion
This study reports on the largest population in which renal
changes after RDN were systematically assessed by MRA.
The incidence of new or progression of pre-existing vascular
abnormalities was 3.1% (95% CI −0.4 to 6.7) of treated pa-
tients and 1.5% (95% CI −0.2 to 3.2) of treated arteries after a
median follow-up of 12months after RDN. Two patients had a
new renal artery stenosis and one patient showed progression
of pre-existing stenosis. No new or progressed aneurysms,
dissections or renal parenchymal anomalies were observed.
The incidence of renal changes after RDN is described in
many studies and mostly varies from 0% to 4.4%, with a few
outliers of 24% and even 30.7% [8, 10–18]. The ability to
compare the incidences reported in the literature is hampered
by the large variations in study design, such as imaging mo-
dality used, ablation catheter used and the morphological ab-
normalities that were of interest to the investigators. Few
studies made a special effort to primarily investigate the renal
artery changes after RDN [14, 16, 17].
Lambert et al. showed an incidence of 2.6% (95% CI
−1.0 to 6.2) (two out of 76 patients) of new or
progressed renal artery stenosis, using MRA or CTA,
6 months after RDN [16]. In none of these cases lumen
reduction exceded 70%. In the mentioned study, renal
artery imaging was also systematically evaluated as part
of the primary study aim. It is unclear whether they
observed other renal abnormalities. As in our population,
the Symplicity catheter was used most frequently with a
comparable mean number of ablations per artery.
Fig. 1 Radiofrequency ablation
point on the procedural
angiography (red arrow, panel a)
near the location where on the
magnetic resonance angiography
(MRA) post renal denervation
(RDN) a new renal artery stenosis
was observed (red arrow, panel b)
Table 3 Patient-related parameters during the follow-up MRA
All patients (n = 96)
Body mass index (kg/m2) 29 ± 5
No. of antihypertensive drugs 4 (IQR 3–5)
Office SBP/DBP (mmHg) 164/96 ± 25/16*
Office heart rate (bpm) 70 ± 12
eGFR (ml/min/1.73 m2) 82 ± 19
Time RDN – follow-up MRA in days 366 (IQR 213–397)
Data are presented as mean ± standard deviation or as median with inter-
quartile range (IQR)
SBP systolic blood pressure,DBP diastolic blood pressure, bpm beats per
minute, eGFR estimated glomerular filtration rate, MRA magnetic reso-
nance angiography, RDN renal denervation
*Significant reduction, compared to baseline (p < 0.001)
Table 4 Characteristics of patients with vascular changes
Patient 1 Patient 2 Patient 3
Office SBP/DBP (mmHg)
Baseline 197/115 180/95 173/111
Follow-up 183/99 190/90 186/121
eGFR (mL/min/1.73 m2)
Baseline >90 48 75
Follow-up >90 66 >90
Time MRA1 – RDN (days) 90 177 207
Time RDN – MRA2 (days) 357 355 192
Ablations in artery of interest 8 4 5
Lumen reduction, %
Baseline N/A N/A <25%
Follow-up 25–49% 25–49% 50–74%
Artery type Main Main Main
Arterial segment 2 1 1
Kidney length, side stenosis (mm)
Baseline 125 105 94
Follow-up 123 103 98
Data are presented as absolute numbers or percentage
SBP systolic blood pressure, DBP diastolic blood pressure, eGFR esti-
mated glomerular filtration rate, MRA magnetic resonance angiography,
RDN renal denervation, N/A not applicable
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Zhang et al. also specifically investigated the effects of
RDN on the renal arteries, using a multidetector spiral CTA
[14]. In a population of 39 treated patients, no renal artery
stenoses, aneurysms or dissections were observed before and
12 months after RDN (incidence 0% [95% CI −4.4 to 4.4]).
Interestingly, they showed an increase in cases with renal ath-
erosclerosis and a significant increase in plaque burden in the
38 control patients, while there were no differences in the
RDN group. In the Prague-15 study, an RCT comparing the
BP-lowering efficacy of RDN to pharmacotherapy, also only
(minimal) progression of atherosclerotic lesions was ob-
served, in 24% of the 37 treated patients by CTA assessment
after 12 months [10].
Recently, Schmid et al. reported on a cohort of 51 resistant
hypertensive patients, treated with RDN [17]. In accordance
with our study, an MRAwas performed before RDN and after
a median follow-up of 12 months, and a median number of six
ablations was applied. The investigators did not observe any
anomalies in renal arteries or parenchyma.
ContemporaryMRAtechnique is known for its high sensitiv-
ity and specificity (at least 90% and 92%, respectively) for the
detection of main renal artery stenosis, comparable to CTA
[29–31]. In RDN studies, renal vascular changes were often
assessed using duplex ultrasonography [11, 12, 15, 18].
However, studies that primarily aimed at investigating changes
in renal arteries usingMRAorCTAobserved incidences that did
not differ much from those found using duplex ultrasonography
[11, 12, 14–18]. An explanation for thismight be a lack of preci-
sion, due to small sample sizes and a small number of events.
Based on the evaluation of the procedural angiographies,
we concluded that only in one patient the newly observed
stenosis was located in an ablated area. A relationship with
the procedure could therefore not be excluded. In the other
two patients, there was no reason to believe that the new or
progressed lumen reduction after RDNmay have been a result
of the ablations (very proximal stenosis and more distally
ablated). The natural history of renal vascular anomalies with-
in 1 year in hypertensive patients who had no stenosis at
baseline is not often investigated. In 1998, Caps and co-
workers reported a cumulative incidence of progression to
≥60% stenosis of at least 5% after 1 year in patients who were
initially wrongly suspected of having atherosclerotic renal ar-
tery stenosis (investigated by duplex ultrasonography) [32].
The cumulative incidence of progression in patients with
pre-existing stenosis was almost five times higher. Two other
studies showed that in a population of resistant hypertensive
patients with relatively high vascular morbidity, occurrence or
progression of renal artery atherosclerosis is very likely [33,
34]. For a correct interpretation of the currently presented
results, a comparison with (randomized) control patients and
differentiation between atherosclerosis and other causes of
renal artery stenosis would be useful. However, this differen-
tiation is radiologically challenging.
It is important to realize that most RDN procedures were
performedwith the Symplicity catheter and that themeannum-
ber of ablations was six per artery. Recent studies have shown
thatwith thisdeviceavariabledegreeofdenervation isobtained
[35, 36]. This may have influenced our findings since one may
assume that insufficient ablation energy could result in less
renal artery or kidney injury in some of these patients. Due to
thesmallnumberofabnormalities inourstudy,wewerenotable
to investigate the relationship between number of ablations and
the occurrence of abnormalities. Presently, newer devices are
available, a higher number of ablation points is advised and
different technologies for denervation have been introduced.
The incidence of vascular changes following treatment with
these novel devices should therefore be a subject of interest in
future studies. The imaging protocols presented in this paper
may serve as a basis for these studies.
The strengths of this study are the multicentre design, the
assessment by MRA and the standardized blinded evaluation
of scans. We made a great effort to objectively review the
MRAs, which improved the quality of our results.
Importantly, all scans were performed according to the
centre-specific standard of care, which means that none of
the MRAs had a clinical indication. This results in a good
reflection of the real incidence of vascular changes after
RDN for this device and dosage. Also, the multicentre aspect
and consequently differences in scan parameters contribute to
better representative results.
An important limitation of this study is the absence of a
reference group, i.e. a group of individuals suitable for RDN,
yet not receiving RDN. As discussed above, vascular changes
could be due to radiofrequency ablation or just be a natural
history of disease. AlthoughMRA has sufficient sensitivity to
detect stenoses, this technique does not allow for differentia-
tion between atherosclerosis and other causes of renal artery
stenosis. Finally, we cannot rule out that selection based on
complete follow-up (availability of two MRAs) may have
influenced our results, although follow-up MRAs had no clin-
ical indication. An overestimation of renal changes after RDN
could theoretically be the consequence.
In conclusion, basedon the largest population inwhich renal
changes after RDNwere systematically assessed byMRA, the
total incidence of vascular changes after a median time of
12 months post-renal denervation was 3.1% (95% CI −0.4 to
6.7). The procedural angiographies showed that ablationswere
applied near the observed stenosis in only one of the three pa-
tients. The results of this study indicate that the risks ofRDN to
the renal arteries and parenchyma appear to be limited.
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